Physician profile
Mark S Reiter
NPI 1902864408
$1,521.16
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $104 · 2021: $191 · 2022: $389 · 2023: $232 · 2024: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $239.26 | 2019-2024 | Mounjaro, Zepbound, Trulicity |
| Otsuka America Pharmaceutical, INC. | $176.06 | 2022-2024 | Nuedexta, Rexulti |
| Jazz Pharmaceuticals INC. | $161.36 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.83 | 2019-2022 | |
| Pfizer INC. | $112.18 | 2022-2024 | |
| Eisai INC. | $109.76 | 2020-2022 | |
| Astellas Pharma US INC | $109.65 | 2019 | |
| Janssen Pharmaceuticals, INC | $85.99 | 2024 | Spravato |
| Novo Nordisk INC | $79.10 | 2020-2022 | |
| Abbvie INC. | $70.26 | 2022 | |
| Merck Sharp & Dohme LLC | $58.44 | 2021-2023 | Belsomra |
| Astrazeneca Pharmaceuticals LP | $37.43 | 2019-2024 | Farxiga |
| Amgen INC. | $32.47 | 2020-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.95 | 2021 | |
| Glaxosmithkline, LLC. | $28.24 | 2019-2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $20.95 | 2022 | |
| Halozyme INC | $13.69 | 2023 | |
| Avanir Pharmaceuticals, INC. | $12.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Reiter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.